Brain-derived neurotrophic factor (BDNF), a critical modulator in the neurodevelopment and maintenance of both central and peripheral nervous systems, is regarded as a potential therapeutic target of Parkinson's disease (PD). However, its association with PD remains unclear and the data are inconsistent. To explore the correlation, studies reporting BDNF levels in PD patients and healthy controls are searched and a sample of 1496 participants are pooled in the meta-analysis, demonstrating significantly decreased serum levels of BDNF in PD patients when compared with the healthy controls (SMD = −1.03; 95% CI [−1.83, −0.23]; P = .012). Meta-regression analysis indicates gender is an important confounding factor (Adj R 2 = 69.20%, p = .004, I 2 res = 90.64%), whereas age (Adj R 2 = 11.91%, P = .95, I 2 res = 96.86%), H-Y stages of PD progression (Adj R 2 = −30.18%, P = .612, I 2 res = 96.62%) and MoCA score assessed cognitive impairment (Adj R 2 = 2.18%, P = .517, I
Introduction
Parkinson's disease (PD) is a chronic neuron-degenerative disorder in the central nervous system. Both genetic and environmental factors are believed to contribute to its pathogenesis (Kalia and Lang, 2015) . The pathological changes of the disease are characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta with or without the presence of intraneuronal proteinaceous inclusions, resulting in PD's motor and non-motor symptoms (Dauer and Przeborski, 2003; Ziemssen and Reichmann, 2007) , including depression, cognitive impairment and reduced physical capacity. Currently, PD is the second most common neurodegenerative disorder worldwide. Yet there is no cure for the disease, but treatments directed at improving symptoms.
Brain-derived neurotrophic factor (BDNF), a member of the nerve growth factor family of proteins, is secreted and abundant in the mammalian central nervous system (Park and Poo, 2013) . It is a major promoter of synaptic plasticity, as well as neuronal survival, differentiation, maintenance, and regeneration (Binder and Scharfman, 2004; Cohen-Cory et al., 2010; Park and Poo, 2013) . Reduced BDNF expression in the substantia nigra in animal results in similar symptoms of PD (Baquet et al., 2005; Porritt et al., 2005) , whereas artificial increase of BDNF in experimental animal models of PD rescues degenerating dopamine neurons (Isacson et al., 1995; Levivier et al., 1995; Tsukahara et al., 1995; Hung and Lee, 1996; Murer et al., 2001 ). Consistently, a lot of improving treatments of PD are accompanied by BDNF enhancement (Okazawa et al., 1992; Bousquet et al., 2009; Naoi and Maruyama, 2009; Gyarfas et al., 2010; Li et al., 2010a; Li et al., 2010b; Zhao et al., 2010) . All these results suggest that dysfunction of BDNF is involved in the pathogenesis of PD and provide cautious optimism that BDNF could act as a therapeutic agent of PD. However, the correlation between BDNF levels and PD remains unclear, as relatively few studies have explored this relationship and not all data are consistent. Here, we perform a systematic review and meta-analysis of related studies.
Materials and Methods

Search strategy and study selection
The databases of the Cochrane Library, PubMed and CNKI are searched by two independent researchers to identify relevant studies from inception to July 11, 2017. The following search criteria are used:
limitation. The references of relevant reviews and included studies are also screened for eligible studies.
Studies are retrieved and assessed for eligibility with the following inclusion criteria: human study, case-control study, having data necessary for meta-analysis. Exclusion criteria include: publications with overlapping data, review, abstract, letter and case report, and studies without usable data.
Data extraction
Data were independently extracted from each study by two investigators and disagreements are resolved by discussion. The main data extracted include: the first author's last name, year of publication, origin of the study population, sample size, mean age of the participants, the percentage of women included in PD and control sample, the method of detecting BDNF. The mean BDNF levels and their corresponding standard deviations are also extracted, or, are estimated from median, range, and the sample size, if they are not directly reported (Hozo et al., 2005) .
Statistical analysis
We used Stata 14 software to conduct the meta-analysis. The pooled standardized mean differences (SMDs) with 95%CIs are calculated to compare the BDNF level between PD and control group. Between-study heterogeneity is assessed using I 2 statistic method (Higgins et al., 2003) and Cochran's Q-statistic (Cochran, 1954) . When significant heterogeneity is observed (P < .05, I 2 > 50%), a random effects model of DerSimonian and Laird is applied to pool data (DerSimonian and Laird, 1986) . Otherwise, the fixed-effect model of Mantel-Haenszel method is adopted (Mantel and Haenszel, 1959) . Potential publication bias is evaluated by visual inspection of a funnel plot. And the Egger's linear regression test (P < .05 is considered significant) is also performed (Egger et al., 1997) , except in cases where included studies are fewer than ten. Sensitivity analysis is performed to assess the influence of a single study on the overall effect estimated by omitting one study at a time during repeated analyses. The temporal effect is also evaluated with a cumulative meta-analysis. Meta-regression analysis is further performed to analyze the potentially important covariates of subject's age, gender, as well as the severity level of the patients and their cognitive impairment. Subgroup analysis is employed to evaluate the effect of geographic location and human species on serum level of BDNF.
Results
Study selection and characteristics of eligible studies
The study search is shown in Fig. 1 . Potential articles are found through literature search. After screening of the title and abstract, twenty-two studies are identified for full-text review (Zhang et al., 2008; Salehi and Mashayekhi, 2009; Palhagen et al., 2010; Scalzo et al., 2010; Teixeira et al., 2010; Sun, 2011; Leverenz et al., 2011; Ventriglia et al., 2013; Angelucci et al., 2015; Chen et al., 2015; Costa et al., 2015; Liu et al., 2015; Brockmann et al., 2016; Khalil et al., 2016; Wang et al., 2016; Xiao, 2016; Ye et al., 2016; Brockmann et al., 2017; Khalil et al., 2017; Rydbirk et al., 2017; Siuda et al., 2017; Wang et al., 2017) . Then, two studies are excluded for overlapping data (Khalil et al., 2017; Wang et al., 2017) , and eleven studies from twenty publications are finally included in the meta-analysis (Zhang et al., 2008; Salehi and Mashayekhi, 2009; Scalzo et al., 2010; Sun, 2011; Ventriglia et al., 2013; Chen et al., 2015; Brockmann et al., 2016; Khalil et al., 2016; Wang et al., 2016; Ye et al., 2016; Siuda et al., 2017) , and their detailed characteristics are presented in Table 1 .
BDNF levels in PD
The data regarding BDNF in CSF or brain tissue of PD patients are very limited. We only find two qualified studies on CSF (Zhang et al., 2008; Salehi and Mashayekhi, 2009 ) and one on brain tissue (Rydbirk et al., 2017) , whose data are contradictory. More studies would be needed to fully understand how BDNF works in the whole body system. Data from nine studies including 838 PD patients and 657 healthy controls are analyzed for serum BDNF level in PD patients. Since obvious between-study heterogeneity among those studies (I 2 = 97.5%, p = .000) is observed, the random-effects model of DerSimonian and Laird is applied to pool the data. The pooled sample consisting of 1496 subjects demonstrate that serum BDNF level is significantly decreased in PD patients compared to healthy controls (SMD = −1.03; 95% CI [−1.83,-0.23]; P = .012)( Fig. 2A) . Subgroup analysis by geographic locations shows that the heterogeneity is still high in both non-Chinese populations (mostly Caucasian) (I 2 = 95.2%, p = .000) (Fig. 2B ) and
Chinese populations (I 2 = 93.9%, p = .000) (Fig. 2C) . Therefore geographic location or human species is not a main source of heterogeneity.
No obvious asymmetry is detected in the funnel plot (Online Resource 1). But Egger's test is not applied since the involved studies are fewer than ten. Sensitivity analysis by omitting one study by turns shows that no single study significantly changes the pooled results (Online Resource 2). Cumulative analysis further excludes a temporal effect (Online Resource 3). In meta-regression analysis, age and gender are analyzed for their effects on overall results individually. Gender appears to have moderating effects (P = .004, Adj R 2 = 69.20%, Fig. 3A ), whereas age shows no effects at all (P = .195,Adj R 2 = 11.91%, Fig. 3B ).
The effect of (A) gender and (B) age on the differences of serum BDNF between PD patients and healthy controls. The sizes of the bubbles are proportional to study weight.
Disease severity
Considering the clinical heterogeneity of PD, PD patients are classified in different ways. The Hoehn and Yahr scale (H-Y) is widely used to define the various stages of the disease, by which PD patients are classified into 5 stages from least to most severe according to their severity levels (Hoehn and Yahr, 1967) . And the Montreal Cognitive Assessment (MoCA) provides a global assessment of cognitive function with a score of 26 or above considered normal (Nasreddine et al., 2005) . Among the screening results, four eligible studies provided H-Y stages for the PD patients and five eligible studies with MoCA scores were found. In each of these nine studies, PD patients were divided into two subgroups by their authors for various purposes. Because of different cutoff values set in different studies, we are unable to pool them together for meta-analysis. Instead, meta-regression analysis is performed to explore the relationship between the level of serum BDNF and the progress of PD (Online Resource 4, Fig. 4A ) as well as the cognitive function of PD patients (Online Resource 5, Fig. 4B ) respectively. With a sample of 487 PD patients, we show that H-Y stages show few effects on serum concentration of BDNF (P = .612, Adj R 2 = −30.18%). Similarly, serum BDNF level is hardly influenced by
MoCA score assessed cognitive impairment in a sample of 584 PD patients (P = .517, Adj R 2 = 2.58%).
Two eligible studies on cerebrospinal fluid (CSF) (Zhang et al., 2008; Salehi and Mashayekhi, 2009 ) and one study on brain tissue (Rydbirk et al., 2017 ) meet our inclusion criteria, but no further analysis is performed due to the limited number of studies.
Discussion
Although there are many new advances in the understanding of the molecular mechanism of BDNF, a potential therapeutic target of PD, no clear conclusion about its association with PD has been made and inconsistency exists among documented data. To explore this, a metaanalysis has been conducted in the present study. This meta-analysis includes nine case-control studies assessing 838 PD patients and 657 healthy controls and provides evidence of a significant reduction in BDNF peripheral blood levels in PD patients when compared with healthy controls (Fig.2A) . No obvious publication bias is detected in the included studies by visual inspection of the funnel plot (Online Resource 1). Sensitivity analysis indicates that the significant association between BDNF and PD is very stable and no single one of the studies is able to fully explain the strong heterogeneity among studies or significantly change the overall result (Online Resource 2). And the statistical power is increased when the overall sample size is increased by pooling independent studies, despite the existence of the high heterogeneity (Online Resource 3).
Although four out of nine studies are from China (Sun, 2011; Chen et al., 2015; Wang et al., 2016; Ye et al., 2016) , their participants are selected and the serum BDNF concentration is measured independently in different provinces. Studies outside China are even performed in different countries (Scalzo et al., 2010; Ventriglia et al., 2013; Brockmann et al., 2016; Khalil et al., 2016; Siuda et al., 2017) , the majority of whose participants are Caucasian. Subgroup analysis shows that geographic locations or human species are not the main sources of the heterogeneity, which remains significant in both Chinese and nonChinese subgroups. However, all subgroups present a trend of reduced BDNF in peripheral blood of PD patients when compared with healthy controls (Fig. 2B) . In the more homogenous Chinese subgroup, a significant reduction of serum BDNF in PD patients is achieved (Fig. 2C) .
Noticeably, PD itself is a clinically, pathologically and genetically heterogeneous disorder (Kalia and Lang, 2015) , whose underlying pathological mechanism has not been fully elucidated. It is possible that there is some variation of basal serum BDNF level in different subtypes or stages of PD patients. And in Brockmann 2016 study, 49.65% of PD patients are carriers of the LRRK2 pathogenic mutation, which generally accounts for 5-6% of familial and 1-2% of sporadic PD cases (Li et al., 2014) . With the difference between sporadic PD patients and LRRK2 derived PD patients remains unclear, we are not sure whether it is appropriate to include the Brockmann 2016 study in this meta-analysis, or whether this is the underlying reason for the apparent contradiction between the data from this study and the overall result.
Moreover, BDNF has been widely studied as a potential diagnostic, prognostic and therapeutic agent in many neuronal cell injury circumstances. A lot of factors have been documented to affect its concentration in serum, such as age (Siuda et al., 2017) , gender (Brockmann et al., 2016) , various medications (Okazawa et al., 1992; Bousquet et al., 2009; Naoi and Maruyama, 2009; Gyarfas et al., 2010; Li et al., 2010a; Li et al., 2010b; Rylander et al., 2010; Zhao et al., 2010) and individual cognitive performance (Khalil et al., 2016; Wang et al., 2016; Siuda et al., 2017; Wang et al., 2017) . Due to the insufficient data of individual cognitive performance and specific treatment, we could not evaluate their effect on the overall result. It is worth mentioning, however, that in Ventriglia 2013 study, all PD patients have claimed to receive treatment with levodopa, the most effective medication available for the treatment of PD. And levodopa, as a neuroprotective reagent, has been shown to stimulate BDNF secretion and increase its level in different animal models (Okazawa et al., 1992; Rylander et al., 2010) . Thus, the observed enhancement in serum BDNF of PD patients in this study could be stimulated by levodopa therapy. On the other hand, the majority of PD patients in China lack systemic treatment, which might contribute to the more significant decrease of serum BDNF in PD patients of Chinese subgroup. Meta-regression analysis provides evidence that gender is a confounding factor that contributes to the heterogeneity among eligible studies (P = .004, Fig. 3A ), whereas age (P = .195, Fig. 3B ), H-Y stages of PD progression (P = .612, Fig. 4A ) and MoCA score assessed cognitive impairment (P = .517, Fig. 4B) show no moderating effect. Therefore, the between-study heterogeneity in this meta-analysis could be partially explained by gender distribution differences.
Variability in the methods used to measure circulating BDNF in the serum could have affected our results, which is reported to be one of the main sources of inconsistencies among studies (Polacchini et al., 2015) . Previous research demonstrates that multiple transcriptions start sites and alternative splicing result in > 18 BDNF transcripts (Pruunsild et al., 2007) . In combination with various post-translational modifications of the protein, including but not limited to cleavage (Mowla et al., 1999) and phosphorylation (Deng et al., 2013) , BDNF protein is highly heterogeneous and multifunctional. All nine studies included in this meta-analysis measure BDNF in the serum by immunoassays, which are basically antigen-antibody interactions. Consequently, the specificity and sensitivity of the antibody used to detect active BDNF is very Fig. 1 . Flowchart of the literature search. Table 1 Characteristics of studies on the association between serum BDNF levels and PD risk. 66.2 ± 8.4 6.8 ± 3.9 (ng/ml) ELISA Khalil (Khalil et al., 2016) critical, which will dramatically affect the outcome of the measurement (Polacchini et al., 2015) . But the immunoassay kits used in these studies are applied by different companies and differ for the type of detection antibodies and signal capture, which will definitely contribute to heterogeneity among studies in the meta-analysis.
To the best of our knowledge, this is the first meta-analysis that investigates the correlation of BDNF levels in PD patients compared with healthy controls. Our study indicates that peripheral BDNF levels are reduced in PD patients when compared with healthy controls. This result supports the idea that BDNF is involved in PD pathology. However, caution should be taken when interpreting the result because of the high level of heterogeneity among studies as well as multiple affecting factors. There is a need for generalization of the protocol for sampling process and detection methods. And in future case-control studies, more comprehensive reporting of all relevant data, including, but not limited to, patients' symptom type and severity, as well as types of treatment, would enable clarification of the role of BDNF in the disease development and benefit its application as PD treatment.
Conclusions
